Neoadjuvant chemoradiotherapy for esophageal carcinoma

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Neoadjuvant chemoradiotherapy is a common treatment for esophageal carcinoma, aiming to improve patient survival.
• The efficacy of neoadjuvant chemoradiotherapy in esophageal cancer management remains a subject of ongoing debate.
• This study retrospectively analyzes the outcomes of patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.

Purpose of the Study:

• To evaluate the impact of neoadjuvant chemoradiotherapy on survival outcomes in patients with esophageal carcinoma.
• To assess the rates of tumor down-staging and complete pathological response following neoadjuvant chemoradiotherapy.
• To determine the effect of neoadjuvant chemoradiotherapy on surgical morbidity and mortality in esophageal cancer patients.

Main Methods:

• A cohort of 115 patients undergoing esophagectomy between 1999 and 2004 was studied.
• Fifty-six patients received neoadjuvant chemoradiotherapy (cisplatin, 5-fluorouracil, 45 Gy radiation) before surgery.
• Fifty-nine patients underwent surgery alone; outcomes were prospectively determined with full follow-up.

Main Results:

• Neoadjuvant chemoradiotherapy achieved down-staging in 43-46% of patients across T, N, and TNM classifications.
• A complete pathological response was observed in 13% of patients receiving neoadjuvant chemoradiotherapy.
• Four-year survival was 33% with neoadjuvant chemoradiotherapy versus 19% with surgery alone; no significant differences in morbidity or mortality were noted.

Conclusions:

• Neoadjuvant chemoradiotherapy effectively down-stages esophageal tumors and achieves pathological response in a subset of patients.
• The treatment was not associated with increased perioperative mortality or postoperative morbidity.
• This non-randomized study suggests neoadjuvant chemoradiotherapy may be associated with improved survival outcomes for esophageal carcinoma.